{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:41:35Z","timestamp":1763106095924,"version":"build-2065373602"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review aims to summarize current recommendations for the management of serious infections, such as bloodstream infections (BSIs) and ventilator-associated pneumonia, caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens, focusing on evidence from randomized controlled trials (RCTs) and emerging treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Vancomycin, linezolid, and daptomycin represent the main therapeutic options for the management of methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      infections; among newer agents, ceftobiprole has recently gained approval for BSI treatment. For vancomycin-resistant\n                      <jats:italic toggle=\"yes\">Enterococcus faecium<\/jats:italic>\n                      BSIs, linezolid and daptomycin remain commonly employed despite the lack of comparative RCTs guiding treatment decisions. The management of MDR\/XDR Gram-negative infections is challenging, owing to sparse clinical trials for robust guidance and rapid emergence of diverse resistance mechanisms. New beta-lactam\/beta-lactamase inhibitor combinations remain the cornerstone of treatment for carbapenem-resistant Enterobacterales and carbapenem-resistant\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      . Cefiderocol and the combination of ceftazidime-avibactam plus aztreonam represent the current last-resort options for metallo-\u03b2-lactamase producers. For carbapenem-resistant\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                      , sulbactam\u2013durlobactam has demonstrated at least comparable activity compared to colistin but is unavailable in most countries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Optimal management of serious infections by MDR\/XDR pathogens requires up-to-date knowledge of evolving treatment options and resistance mechanisms. Further high-quality clinical trials are needed to guide evidence-based therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mcc.0000000000001307","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T12:02:32Z","timestamp":1757073752000},"page":"488-496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Management of MDR\/XDR severe infections in the critically ill"],"prefix":"10.1097","volume":"31","author":[{"given":"Luca","family":"Mezzadri","sequence":"first","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore"},{"name":"Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated Gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R11-20251029","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","author":"Tong","year":"2025","journal-title":"JAMA"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"R15-20251029","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00059-22","article-title":"Therapeutics for vancomycin-resistant enterococcal bloodstream infections","volume":"36","author":"Cairns","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jiph.2022.10.017","article-title":"The combination of daptomycin with \u03b2-lactam antibiotics is more effective than daptomycin alone for vancomycin-resistant Enterococcus faecium bloodstream infection","volume":"15","author":"Chuang","year":"2022","journal-title":"J Infect Public Health"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40121-022-00754-1","article-title":"The combination of daptomycin with fosfomycin is more effective than daptomycin alone in reducing mortality of vancomycin-resistant enterococcal bloodstream infections: a retrospective, comparative cohort study","volume":"12","author":"Tseng","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"e0255122","DOI":"10.1128\/spectrum.02551-22","article-title":"A high daptomycin dose is associated with better bacterial clearance in infections caused by vancomycin-resistant Enterococcus faecium regardless of daptomycin minimum inhibitory concentration in a rat infective endocarditis model","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"R19-20251029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s12879-025-10749-1","article-title":"Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022","volume":"25","author":"Lodise","year":"2025","journal-title":"BMC Infect Dis"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, noninferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41564-020-0737-6","article-title":"A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii","volume":"5","author":"Luna","year":"2020","journal-title":"Nat Microbiol"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","article-title":"Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection","volume":"386","author":"Eckburg","year":"2022","journal-title":"N Engl J Med"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"e049481","DOI":"10.1136\/bmjopen-2021-049481","article-title":"Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTART\u00c9): protocol for a randomised, pragmatic trial","volume":"11","author":"Mar\u00edn-Cand\u00f3n","year":"2021","journal-title":"BMJ Open"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1248\/bpb.b24-00834","article-title":"Efficacy of de-escalation to cefmetazole in patients with bacteremic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"48","author":"Namiki","year":"2025","journal-title":"Biol Pharm Bull"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dkac323","article-title":"Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/jac\/dkac038","article-title":"Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41467-024-48296-z","article-title":"Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries","volume":"15","author":"Kakaraskoska Boceska","year":"2024","journal-title":"Nat Commun"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1002\/sim.10168","article-title":"Determining sample size in a personalized randomized controlled (PRACTical) trial","volume":"43","author":"Turner","year":"2024","journal-title":"Stat Med"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14787210.2025.2473047","article-title":"Past, present, and future perspectives on aztreonam and avibactam","volume":"23","author":"Bush","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R40-20251029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00389-17","article-title":"Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam","volume":"61","author":"Zhang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13543784.2024.2326028","article-title":"Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials","volume":"33","author":"Paterson","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"R42-20251029","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R43-20251029","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"25","author":"Shields","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R44-20251029","doi-asserted-by":"crossref","first-page":"e0090724","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-20251029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"R46-20251029","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"R47-20251029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/23744235.2024.2396882","article-title":"Synergistic efficacy of ceftazidime\/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model","volume":"57","author":"Montero","year":"2025","journal-title":"Infect Dis (Lond)"},{"key":"R48-20251029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R49-20251029","doi-asserted-by":"crossref","first-page":"105082","DOI":"10.1016\/j.cmicom.2025.105082","article-title":"Contemporary antimicrobial treatment rationale of Stenotrophomonas maltophilia infections: a narrative review","author":"Turnidge","year":"2025","journal-title":"CMI Commun"},{"key":"R50-20251029","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:49:50Z","timestamp":1761734990000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCC.0000000000001307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000001307","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"type":"print","value":"1070-5295"},{"type":"electronic","value":"1531-7072"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}